Charles Schwab
ALDX icon

Charles Schwab’s Aldeyra Therapeutics ALDX Stock Holding History

Charles Schwab’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$235K Sell
139,029
-13,758
-9% -$60.3K ﹤0.01% 3287
2025
Q4 		$791K Buy
152,787
+2,309
+2% +$11.9K ﹤0.01% 3002
2025
Q3 		$785K Sell
150,478
-7,060
-4% -$36.8K ﹤0.01% 3031
2025
Q2 		$603K Buy
157,538
+19,553
+14% +$50.5K ﹤0.01% 3076
2025
Q1 		$793K Buy
137,985
+1,252
+0.9% +$7.4K ﹤0.01% 2920
2024
Q4 		$682K Hold
136,733
– – ﹤0.01% 3047
2024
Q3 		$737K Hold
136,733
– – ﹤0.01% 3018
2024
Q2 		$453K Buy
136,733
+11,208
+9% +$43.9K ﹤0.01% 3240
2024
Q1 		$410K Hold
125,525
– – ﹤0.01% 3099
2023
Q4 		$441K Hold
125,525
– – ﹤0.01% 3123
2023
Q3 		$839K Hold
125,525
– – ﹤0.01% 2860
2023
Q2 		$1.05M Buy
125,525
+103,324
+465% +$1.02M ﹤0.01% 2756
2023
Q1 		$220K Hold
22,201
– – ﹤0.01% 3137
2022
Q4 		$155K Hold
22,201
– – ﹤0.01% 3221
2022
Q3 		$119K Hold
22,201
– – ﹤0.01% 3211
2022
Q2 		$89K Sell
22,201
-110,707
-83% -$381K ﹤0.01% 3299
2022
Q1 		$591K Buy
132,908
+4,523
+4% +$18K ﹤0.01% 3051
2021
Q4 		$514K Buy
128,385
+3,699
+3% +$28.2K ﹤0.01% 3136
2021
Q3 		$1.09M Sell
124,686
-413
-0.3% -$3.79K ﹤0.01% 2842
2021
Q2 		$1.42M Buy
125,099
+106,972
+590% +$1.29M ﹤0.01% 2820
2021
Q1 		$216K Hold
18,127
– – ﹤0.01% 3305
2020
Q4 		$125K Hold
18,127
– – ﹤0.01% 3302
2020
Q3 		$135K Buy
+18,127
New +$117K ﹤0.01% 3229
2020
Q2 		– Sell
-52,683
Closed -$131K – 3321
2020
Q1 		$131K Sell
52,683
-4,964
-9% -$22.3K ﹤0.01% 3080
2019
Q4 		$335K Buy
57,647
+4,111
+8% +$23.7K ﹤0.01% 2952
2019
Q3 		$283K Sell
53,536
-8,000
-13% -$43.1K ﹤0.01% 2980
2019
Q2 		$370K Buy
61,536
+19,826
+48% +$149K ﹤0.01% 2951
2019
Q1 		$377K Sell
41,710
-5,100
-11% -$43.3K ﹤0.01% 2864
2018
Q4 		$389K Buy
46,810
+17,110
+58% +$175K ﹤0.01% 2848
2018
Q3 		$410K Hold
29,700
– – ﹤0.01% 2908
2018
Q2 		$237K Buy
+29,700
New +$237K ﹤0.01% 3040

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Charles Schwab's ALDX Position: Q1 2026 in Review

Charles Schwab reduced its Aldeyra Therapeutics (ALDX) stake by 9% in Q1 2026, selling an estimated $60.3K and leaving 139,029 shares worth $235K. The position accounts for ﹤0.01% of the portfolio, ranked #3287.

Charles Schwab first reported a position in ALDX in Q2 2018 and has held it in 31 quarters since. The position peaked at $1.42M in Q2 2021. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Charles Schwab held 139,029 shares of Aldeyra Therapeutics worth $235K as of Q1 2026.
  • Charles Schwab sold 13,758 Aldeyra Therapeutics shares in Q1 2026, an estimated $60.3K.
  • Aldeyra Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q1 2026, its #3287 holding.
  • Charles Schwab first reported a position in Aldeyra Therapeutics in Q2 2018 and has held it in 31 quarters since.
  • Charles Schwab's Aldeyra Therapeutics position peaked at $1.42M in Q2 2021.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.